| abstract |
Methods for preventing formation of or disrupting PF4 tetramers are provided. The compounds useful in such methods bind to a PF4 tetramer, dimer, or monomer. The compounds are also useful for preventing formation of or disrupting ultra-large complexes containing a PF4 tetramer and a glycosaminoglycan, and thus have utility toward preventing or treating medical conditions related to the formation of PF4 tetramers, such as HITT and atherosclerosis and toward correcting a platelet imbalance, preventing a decrease in platelet production and increasing high density lipoproteins in a subject. Also provided are compositions and kits containing these compounds and optional medications which cause the formation of PF4 tetramers, and/or medications which disrupt PF4 tetramers. [Formula I] |